68 results about "Gangliosidosis" patented technology

The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis, and for. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liquids with gangliosides, fore example infant formula or infant foods, can be employed according to the invention.

The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10) produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specific binding to the antigen of the original antibodies, but being at the same time less immunogenic. The chimeric antibodies of the invention contain the variable domains of the murine immunoglobulin and the constant regions of the human immunoglobulin; and those humanized, besides containing the constant regions of the human immunoglobulins, they are modified in the region of the murine frameworks (FRs) and in particular in those zones that could be in an antigenic site for the T cells, so several positions of the FRS are human as well. These antibodies can be used in the diagnosis and therapy of different types of tumors. The present invention is also related with use of the antibodies for therapeutical and diagnostic purposes.

The present invention relates to a method for producing glycolipides substance using ganglioside as main component, sand method includes the following steps: pulverizing animal brain tissue, adding 20-100% alcohol solvent to make extraction, in which the ratio of dose of alcohol and weight of brain tissue is 1-10:1, filtering or centrifugalizing, concentrating filtrate, the concentrate and its freeze-dried powder can be diluted with water or mixed with edible auxiliary material, and can be made into the oral brain health-care product with various forms.

This invention discloses a method for extracting ganglioside from animal tissue. The method comprises: extracting ganglioside from animal tissue by using acetone, THF, methanol, chloroform or other polar solvents in buffer containing Na2HPO4, NaH2PO4 or citric acid. During the whole process, ion-exchange water (free of heavy metals) is used, and the treatment temperature is controlled below 35 deg.C to reduce or avoid physiological activity loss. The product is crude ganglioside with some other glycolipids, and has healthcare function.

Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM₁ or GT_1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.

The invention discloses a kind of compound medicine which contains active polypeptide extracted from muscle organism of mammal except human and ganglioside extracted from brain organism of mammal except human. The weight of polypeptide is 6.1-100 times than the sialinic acid in ganglioside. The invention also discloses the manufacturing method and the application in the production of medicine for curing SARS and the heart and brain syndrome caused by SARS. The medicine in the invention can improve metabolism of the heart and brain organism, take part in the growth, differentiation and regeneration of nerve cell in brain, improve the blood circulation of brain and metabolism function of brain, it can cure functional disorder caused by cardiac muscle and brain disease.

The present invention is one kind of ganglioside and bean food composition and its application in delaying senility and improving memory. Based on the modern health care theory of homologous food andmedicine, the present invention combines the main nutritious components of ganglioside and bean food and provides the bean food with ganglioside. Experiment shows that the composition has strong effect of reducing peroxidation of lipoid and that fruit fly taking the said composition has obvious prolonged life and Wistar rat taking the said composite has obviously improved learning and memory capacity. The composition is safe and has no toxicity.

The invention discloses a method for preparing cerebroside carnosine solution and relative cerebroside carnosine injection, wherein the cerebroside carnosine injection contains ganglioside and natural active peptide prepared by present biological purifying technique. And the inventive method comprises that using non-cow animal brain as material, using chloroform/carbinol mixture solvent to obtain the extractive solution with ganglioside from the brain, wherein the volume ratio of the chloroform/carbinol mixture solvent is 1-2:1, then preparing the extractive solution of small molecule peptide whose molecule weight is lower than 8000 from the muscle of non-cow animal, mixing the extractive solutions of step 1 and step 2, while the ganglioside: small molecule peptide is (85-115 mu g) :(5.44-7.36mg). The inventive injection can be used to treat cerebral infarction, coronary disease effectively or the like.

The invention relates to a glioma tumor marker and an application thereof. The glioma tumor marker is disialyl ganglioside, and the structure of the marker is represented by one or more of NeuAc-alpha3-Gal-beta3-GalNAc-beta4(NeuAc-alpha3)-Gal-beta4-Glu-Cer, Gal-beta3-GalNAc-beta4(NeuAc-alpha8-NeuAc-alpha3)-Gal-beta4-Glu-Cer, GalNAc-beta4(NeuAc-alpha8-NeuAc-alpha3)-Gal-beta4-Glu-Cer and NeuAc-alpha8-NeuAc-alpha3-Gal-beta4-Glu-Cer; wherein NeuAc represents sialic acid, Gal represents galactose, GalNAc represents galactosamine, Glu represents glucose and Cer represents N-fatty acyl-sphingosine. The marker can be used for clearly characterizing glioma tumors.

The present invention relates to selectively controlling the function of a helper T cell. In the present invention, a mouse lacking a gene involved in ganglioside biosynthesis (ganglioside GM3 synthetase gene) (SAT-I KO) was produced and analyzed. As a result, the present invention provides, for example, a method for screening a substance which induces selective suppression of the function of a helper T cell in an immune response, including control of production of a sphingoglycolipid in the helper T cell, and moderation or suppression of an excessive immune response caused by the suppression of the function, that is, a substance having an immunosuppression activity, an anti-asthmatic action and/or an anti-allergic action.